HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

16 RCCA New Jersey Physicians Recognized as 2023 Top Cancer Doctors

Since its inception, Regional Cancer Care Associates has applied cutting-edge therapies, sophisticated diagnostics, and a uniquely personal approach to deliver the highest level of care to individuals and families across the state and close to their homes.

This passion and dedication was once again recognized when 16 doctors from RCCA were named 2023 Top Cancer Doctors as selected by health care research and information company Castle Connolly. The company has built a long-standing reputation as America’s trusted source for identifying top doctors through its exhaustive and independent process of peer nomination, research, review and screening.

Patients who seek care at one of Regional Cancer Care Associates’ 16 New Jersey locations, receive multidisciplinary, state-of-the-art care in an environment that is supportive and hopeful.

Congrats written on clipboard paper with stethoscope
Headshot of Dr. Set Berk
Dr. Seth Berk
Headshot of Dr. Maurice Cairoli
Dr. Maurice Cairoli
Headshot of Dr. James Lee
Dr. James Lee
Headshot of Dr. Rachel Levenbach, MD
Dr. Rachel Levenbach
Headshot of Dr. Stephen Wallace
Dr. Stephen Wallace

They also benefit from choosing a location that is close to home, easing the burden of patients and families who would rather not travel to New York or Philadelphia for the same care. Being treated close also means family and friends are able to provide support and strength so that patients can focus on healing. Additionally, a Journal of Clinical Oncology showed that receiving cancer care close to home reduces hospitalizations.

The physicians named to Castle Connolly’s prestigious list of 2023 Top Cancer Doctors in New Jersey are:

There are more than 850,000 practicing physicians in the U.S., but only 7% are named to the Top Doctors list. The recognition is given following a comprehensive review process conducted by an experienced medical review board. Reviewers consider a doctor’s skills, professionalism, training/qualifications, experience, competence, outcomes and achievements as well as his or her relational skills and empathy toward patients.

RCCA has more than 90 cancer specialists who treat patients at more than 20 RCCA care centers in New Jersey, Connecticut, Maryland and the Washington, D.C., area. Those oncologists see more than 23,000 new patients each year and provide care to more than 225,000 established patients, collaborating closely with their patients’ other physicians.

RCCA is the top choice of many patients due to the comprehensive services offered by its physicians, including the latest in cutting-edge treatments, including immunotherapies and targeted therapy, as well as access to a wide range of clinical trials. In addition to serving patients who have solid tumors, blood-based cancers, and benign blood disorders such as anemia, RCCA care centers also provide infusion services to people with a number of non-oncologic conditions—including multiple sclerosisCrohn’s diseaseasthma, and rheumatoid arthritis — who take intravenously-administered medications.

To learn more about RCCA, call 844-928-0089 or visit RCCA.com.  

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

RELATED ARTICLES

3 RCCA Oncologists Making their Mark in the Garden State – and Beyond

More than 80 medical oncologists and hematologists affiliated with Regional Cancer Care Associates (RCCA) – one of the nation’s largest networks of oncology specialists — are on the frontlines of the fight against cancer in New Jersey, providing care to well over 100,000 people each year in 19 community-based practices across the Garden State.

Learn More

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.